KR100593861B1 - 칼시토닌을 함유한 경구투여용 나노입자의 제조방법 - Google Patents
칼시토닌을 함유한 경구투여용 나노입자의 제조방법 Download PDFInfo
- Publication number
- KR100593861B1 KR100593861B1 KR1020010059028A KR20010059028A KR100593861B1 KR 100593861 B1 KR100593861 B1 KR 100593861B1 KR 1020010059028 A KR1020010059028 A KR 1020010059028A KR 20010059028 A KR20010059028 A KR 20010059028A KR 100593861 B1 KR100593861 B1 KR 100593861B1
- Authority
- KR
- South Korea
- Prior art keywords
- calcitonin
- nanoparticles
- acid
- oral administration
- fatty acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Abstract
Description
칼시토닌이 양전하를 띄게 되는 pH 범위내에서 칼시토닌과 상기 pH 범위내에서 음전하를 띄는 지방산을 이온결합시켜 소수성 복합체를 합성하는 단계와, 상기 단계에 의한 소수성 복합체와 생분해성 고분자를 유기용매에 용해한 것을 소정의 분산매에 분산시켜 칼시토닌이 봉입된 나노입자를 합성하는 단계를 포함함을 특징으로 하는 칼시토닌을 함유한 경구투여용 나노입자의 제조방법을 포함한다.
유효직경(nm) | 로딩량(w/w,%) | 로딩효율(w/w,%) | |
A(1%) | 353.41 | 0.96±0.12 | 96.00±0.12 |
B(3%) | 335.14 | 1.83±0.23 | 53.53±7.67 |
C(5%) | 387.76 | 2.70±0.31 | 54.31±6.20 |
Claims (13)
- 칼시토닌을 함유하는 경구투여용 제제의 제조방법에 있어서,칼시토닌이 양전하를 띄게 되는 pH 5.0∼10의 범위에서 칼시토닌과 상기 pH 범위내에서 음전하를 띄는 지방산을 이온결합시켜 소수성 복합체를 합성하는 단계와,상기 단계에 의한 소수성 복합체와 생분해성 고분자를 물, 완충용액, 친수성 알콜에서 선택된 1종의 분산매에 분산시켜 칼시토닌이 봉입된 나노입자를 합성하는 단계를 포함함을 특징으로 하는 칼시토닌을 함유한 경구투여용 나노입자의 제조방법
- 삭제
- 제 1항에 있어서,상기 지방산은 올레산, 디옥시콜레산, DHA, 리놀레산, 라우레산, DMPG의 군에서 선택된 1종임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 1항에 있어서,생분해성 고분자는 폴리에스테르 계, 폴리메타아크릴산 계에서 선택된 1종의 고분자임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 4항에 있어서,폴리에스테르계 고분자는 폴리락트산, 폴리글리콜산, 폴리(D,L-락트산-코-글리콜산), 폴리(카프로락톤), 폴리(발레로락톤), 폴리(하이드록시 부틸레이트), 폴리(하이드록시 발러레이트)에서 선택된 1종을 포함함을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 4항에 있어서,폴리메타아크릴산계 고분자는 폴리메타아크릴산, 폴리메틸메타아크릴산, 폴리(메타아크릴산-메틸메타아크릴산)에서 선택된 1종을 포함함을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 1항에 있어서,칼시토닌-지방산 복합체내의 칼시토닌과 지방산의 조성비는 중량비로 1:1∼1:100임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 삭제
- 제 1항에 있어서,나노입자의 합성시 칼시토닌-지방산 복합체와 생분해성 고분자의 혼합비는 중량비로 칼시토닌:고분자 = 1:10∼1:100 임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 1항에 있어서,칼시토닌-지방산 복합체는 디메틸술폭사이드 또는 디메틸포름알데히드에 용해된 형태의 것임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 삭제
- 제 1항에 있어서,칼시토닌-지방산 복합체와 생분해성 고분자를 함유하는 상기 용해액과 분산매와의 비는 중량비로 1:10∼1:100임을 특징으로 하는 경구투여용 나노입자의 제조방법.
- 제 1항의 방법으로 제조된 나노입자를 유효성분으로 함유하는 경구투여용 골다공증 치료제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010059028A KR100593861B1 (ko) | 2001-09-24 | 2001-09-24 | 칼시토닌을 함유한 경구투여용 나노입자의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010059028A KR100593861B1 (ko) | 2001-09-24 | 2001-09-24 | 칼시토닌을 함유한 경구투여용 나노입자의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030026047A KR20030026047A (ko) | 2003-03-31 |
KR100593861B1 true KR100593861B1 (ko) | 2006-06-30 |
Family
ID=27725278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010059028A KR100593861B1 (ko) | 2001-09-24 | 2001-09-24 | 칼시토닌을 함유한 경구투여용 나노입자의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100593861B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100957123B1 (ko) * | 2007-10-16 | 2010-05-13 | 한국과학기술원 | 생분해성 고분자 나노실린더 및 그의 제조방법 |
KR20230174082A (ko) * | 2022-06-20 | 2023-12-27 | (주) 바이오인프라생명과학 | 약물을 전달하기 위한 초음파 감응형 약물전달체를 생성하는 방법 및 이를 이용한 초음파 감응형 약물전달체 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56140924A (en) * | 1980-04-04 | 1981-11-04 | Teijin Ltd | Calcitonin pharmaceutical preparation |
KR930005635A (ko) * | 1991-09-28 | 1993-04-20 | 베르너 발데그 | 약제학적 조성물 |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
KR20010040726A (ko) * | 1998-02-06 | 2001-05-15 | 유란드 인터내셔날 에스.피.아. | 지질성 물질 및 양친매성 물질을 포함하는 나노입자형태의 약학적 조성물 및 관련 제조방법 |
-
2001
- 2001-09-24 KR KR1020010059028A patent/KR100593861B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56140924A (en) * | 1980-04-04 | 1981-11-04 | Teijin Ltd | Calcitonin pharmaceutical preparation |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
KR930005635A (ko) * | 1991-09-28 | 1993-04-20 | 베르너 발데그 | 약제학적 조성물 |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
KR20010040726A (ko) * | 1998-02-06 | 2001-05-15 | 유란드 인터내셔날 에스.피.아. | 지질성 물질 및 양친매성 물질을 포함하는 나노입자형태의 약학적 조성물 및 관련 제조방법 |
Non-Patent Citations (1)
Title |
---|
abstract; Diaz RV. Llabres M, Evora C.; Joournal of Control release 1999. May. 1; 59(1) pp55~62 * |
Also Published As
Publication number | Publication date |
---|---|
KR20030026047A (ko) | 2003-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9526705B2 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy | |
Peng et al. | A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles | |
JP5384831B2 (ja) | タンパク質ドラッグデリバリ用ナノ粒子 | |
Kumar | Nano and microparticles as controlled drug delivery devices | |
AU2009244742B2 (en) | Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor | |
Li et al. | Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method | |
US20020054914A1 (en) | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein | |
US20110212901A1 (en) | Hyaluronic acid derivative and pharmaceutical composition thereof | |
CN101415442B (zh) | 控释凝胶 | |
CN102327230B (zh) | 一种包裹紫杉烷类药物的蛋白纳米颗粒及其制备方法 | |
JPH09508530A (ja) | 核酸を含む組成物、その調製および使用 | |
CN104415338B (zh) | 主动靶向型抗肿瘤药物及其制备方法 | |
CN111569082B (zh) | 一种包载蛋白多肽类药物外泌体的口服递送系统 | |
ES2637379T3 (es) | Material polimérico de administración de fármacos, método para fabricar el mismo y método para la administración de una composición de administración de fármacos | |
JP2006527265A (ja) | レクチン含有天然物の腸溶性コーティング用組成物 | |
CN102357077B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒及其制备方法 | |
KR20190070653A (ko) | 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법 | |
CN101810560B (zh) | 环孢a聚合物胶束组合物 | |
US20040142887A1 (en) | Antigen-polymer compositions | |
WO2018196819A1 (zh) | 一种包裹有难溶于水药物的蛋白质颗粒及其制备方法 | |
KR100593861B1 (ko) | 칼시토닌을 함유한 경구투여용 나노입자의 제조방법 | |
JP2012509251A (ja) | 放出制御ペプチド製剤 | |
KR101631243B1 (ko) | 신규한 알렌드로네이트 에멀젼 건조물의 제조 방법 및 이를 함유한 약제학적 조성물 | |
CN111467473A (zh) | 多肽hm-3纳米颗粒及其制备方法 | |
Wang et al. | The brief analysis of peptide-combined nanoparticle: Nanomedicine’s unique value |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
E801 | Decision on dismissal of amendment | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040820 Effective date: 20051031 |
|
S901 | Examination by remand of revocation | ||
E902 | Notification of reason for refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130531 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140602 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150602 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170605 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180605 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190604 Year of fee payment: 14 |